Bay City Capital — Full Portfolio

BiotechCambridge, US

Sara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)Mette Kirstine Agger(Director)James G. McArthur(Executive Officer, Director)

Board seatCarl Goldfischer· per SEC Form D

BiotechLouisville, US

Hoyoung Huh(Director, Executive Officer)Sankaram Mantripragada(Executive Officer)Nevan Charles Elam(Executive Officer, Director)Barry Sherman(Director)Morgan Lynn Fields(Executive Officer)

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

Bryan Giraudo(Executive Officer)Faheem Hasnain(Executive Officer, Director)Russell Cox(Director)Renee Gala(Director)Laura Carter, Ph.D.(Executive Officer)Christian Waage(Executive Officer)

BiotechSouth Plainfield, US

Dawn Svoronos(Director)Stuart W. Peltz(Executive Officer, Director)David P. Southwell(Director)Allan S. Jacobson(Director)Mark E. Boulding(Executive Officer)Christine Utter(Executive Officer)

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.

BiotechDeep TechSemiconductorsSouth San Francisco, US

Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Rob Chess(Director)

BoardKeith Crandell(Director)Paul Conley(Director)

Xilio (Xilio Therapeutics) is a clinical-stage biotechnology company developing tumor-selective immunotherapies, including checkpoint inhibitors, T cell engagers and related molecules, for the treatment of cancer.

BiotechHealthtechWaltham, US

Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)Rachel Humphrey(Director)Daniel Lynch(Director)Michael Ross(Director)

HealthtechSt Paul, US

Gary D Blackford(Director)Dan W Gladney(Executive Officer, Director)Scott P Youngstrom(Executive Officer)Rajesh Nihalani(Executive Officer)Peter M DeLange(Executive Officer)Bobby I Griffin(Director)

Board seatCarl Goldfischer· per SEC Form D

HealthtechSan Diego, US

Robert Williamson(Executive Officer, Director, Promoter)John Hutchinson(Executive Officer)Vanessa Jacoby(Executive Officer)Rupert Vessey(Director)

Board seatCarl Goldfischer· per SEC Form D · $3M raise · filed Sep 2016

BiotechSacramento, US

Woodrow A. Myers, Jr.(Director)Vic Schmitt(Director)Chuck Novak(Vice President and Chief Financial Officer of the Issuer)George Barry(Co-Founder of Issuer)Philip H. Coelho(Chief Technology Officer and Co-Founder of Issuer)William Gerber(Chief Executive Officer and President of Issuer)

Board seatCarl Goldfischer· per SEC Form D

BiotechSouth San Francisco, US

Cameron Wheeler(Director)Elaine Jones(Director)Wendye Robbins(Executive Officer, Director)William Slattery(Director)James Scopa(Director)

BoardLuke Evnin(Director)

Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas.

BiotechHealthtechNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Carl Goldfischer, M.D.(Director)Pol Boudes(Executive Officer)Kurt von Emster(Director)Hari Kumar, Ph.D.(Director)Charles A. McWherter, Ph. D.(Executive Officer)

HealthtechMenlo Park, US

LUIS PENA(Executive Officer)CHRISTOPHER GRIFFITH(Executive Officer)KATHLEEN SEBELIUS(Director)DAVID E. COHEN(Director)THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)

Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.

BiotechBoston, US

James Ahlers(Executive Officer)Irwin Scher(Director)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Emad Rizk(Director)

BiotechWatham, US

Joseph Landstra(Director)Kenneth Kornman(Executive Officer, Director)Roger Colman(Director)Dayton Misfeldt(Director)Stephen DiPalma(Executive Officer)James Weaver(Director)

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

Brenton K. Ahrens(Director)Michael W. Dunne(Executive Officer, Promoter)Ronald M. Hunt(Director)Mark Chin(Director)Corey N. Fishman(Executive Officer, Director, Promoter)Robert Hopfner(Director)

KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.

Biotech

BiotechSouth San Francisco, US

John F. Fowler(Executive Officer, Director)Dr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)Christopher J. Kirk(Executive Officer, Director)

Madrigal is a biopharmaceutical company developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious progressive liver disease.

BiotechHealthtech

QUILLIVANT XR is a prescription medication containing methylphenidate, indicated for ADHD treatment.

Medical DevicesNew Jersey, US

Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments.

BiotechHealthtechMedical DevicesBoston, CH

Riad Sherif(Chief Executive Officer)

Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.

ConsumerHealthtechNew MaterialsGeneva, CH

Developing oncology therapeutics for viral-induced tumors; went public February 2021 (VIRX).

BiotechAustin, US

Robert Faulker(Director)Poul Strange(Executive Officer)Navneet Puri(Director)Steven Prestrelski(Executive Officer)Cary McNair(Director)Douglas Baum(Executive Officer, Director)